Video Insights
Advertisement
Advertisement
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Stephen M. Ansell, MD, PhD, explains the importance of making an accurate diagnosis of Hodgkin lymphoma.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
CML clinical expert Nikolai Podoltsev, MD, PhD, especially addresses the capabilities of tyrosine kinase inhibitors.
Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.
Some major themes for practice include identifying patients at risk for early progression and emphasis on quality of life.
Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.
A plant-based diet is significantly associated with a reduced risk of multiple myeloma.
A US population-based study investigated the associations between MGUS and various dietary patterns.
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
An expert panel discusses utilizing molecular strategies to determine treatment decisions for DLBCL.
In this DLBCL roundtable, experts share which novel agents or combinations they are most interested in.
Ruemu Birhiray, MD, leads an expert roundtable on the current treatment pathway in DLBCL.
The expert panel assesses the current and expected utility for clinicians of MRD in DLBCL management decisions.
With insights into next-generation therapies, this discussion explores what’s ahead in the follicular lymphoma landscape.
Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on FL treatment.
Three experts analyze data on combination therapy for FL, including efficacy, safety, and strategy adoption.
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Resistance remains a challenge in central nervous system lymphoma, creating a need for novel therapeutic combinations.
The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors.
Grzegorz Nowakowski discusses the challenges and advances in central nervous system lymphoma treatment.
Nicole Grieselhuber, MD, PhD on results of SEA-CD70 treatment in patients with high-risk MDS.
Drs. Thomas LeBlanc, Jamie Koprivnikar, and Andrew Brunner give their predictions for the future of MDS management.
An expert panel delves into new data regarding the long-term efficacy of luspatercept in MDS.
An expert MDS panel discusses patient reported outcomes, transfusion dependence, and time toxicity.
Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma.
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.